# Natera, Inc.: overview

NTRA · Nasdaq · CIK 1604821 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ntra.md) · [Financials](/companies/ntra/financials.md) · [Filings](/companies/ntra/filings.md) · [Insiders](/companies/ntra/insiders.md)

Latest reported revenue: [$752.8m](/filings/0001628280-26-054525.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054525).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [440](/filings/0001104659-25-107976.md) | [476 d](/filings/0001104659-26-020881.md) | [502](/filings/0001628280-26-032478.md) | [547](/filings/0001628280-26-054525.md) | [592](/filings/0001104659-25-107976.md) | [665 d](/filings/0001104659-26-020881.md) | [697](/filings/0001628280-26-032478.md) | [753](/filings/0001628280-26-054525.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(8.9%)](/filings/0001104659-25-107976.md) | [(13.6%) d](/filings/0001104659-26-020881.md) | [(15.8%)](/filings/0001628280-26-032478.md) | [(20.2%)](/filings/0001628280-26-054525.md) | [(16.5%)](/filings/0001104659-25-107976.md) | [(3.4%) d](/filings/0001104659-26-020881.md) | [(13.4%)](/filings/0001628280-26-032478.md) | [(10.1%)](/filings/0001628280-26-054525.md) |
| Net margin | % | [(7.2%)](/filings/0001104659-25-107976.md) | [(11.3%) d](/filings/0001104659-26-020881.md) | [(13.3%)](/filings/0001628280-26-032478.md) | [(18.5%)](/filings/0001628280-26-054525.md) | [(14.8%)](/filings/0001104659-25-107976.md) | [7.1% d](/filings/0001104659-26-020881.md) | [(12.2%)](/filings/0001628280-26-032478.md) | [(8.9%)](/filings/0001628280-26-054525.md) |
| Diluted EPS | $ per share | [(0.26)](/filings/0001104659-25-107976.md) | not reported | [(0.50)](/filings/0001628280-26-032478.md) | [(0.74)](/filings/0001628280-26-054525.md) | [(0.64)](/filings/0001104659-25-107976.md) | not reported | [(0.60)](/filings/0001628280-26-032478.md) | [(0.47)](/filings/0001628280-26-054525.md) |
| Free cash flow | $m | [35.5 d](/filings/0001104659-25-107976.md) | [34.8 d](/filings/0001104659-26-020881.md) | [22.6](/filings/0001628280-26-032478.md) | [11.7 d](/filings/0001628280-26-054525.md) | [37.0 d](/filings/0001104659-25-107976.md) | [37.8 d](/filings/0001104659-26-020881.md) | [18.0](/filings/0001628280-26-032478.md) | [(8.6) d](/filings/0001628280-26-054525.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [625](/filings/0001558370-24-002083.md) | [820](/filings/0001558370-25-001869.md) | [1,083](/filings/0001104659-26-020881.md) | [1,697](/filings/0001104659-26-020881.md) | [2,306](/filings/0001104659-26-020881.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(74.8%)](/filings/0001558370-24-002083.md) | [(66.0%)](/filings/0001558370-25-001869.md) | [(41.2%)](/filings/0001104659-26-020881.md) | [(13.1%)](/filings/0001104659-26-020881.md) | [(13.4%)](/filings/0001104659-26-020881.md) |
| Net margin | % | [(75.4%)](/filings/0001558370-24-002083.md) | [(66.8%)](/filings/0001558370-25-001869.md) | [(40.2%)](/filings/0001104659-26-020881.md) | [(11.2%)](/filings/0001104659-26-020881.md) | [(9.0%)](/filings/0001104659-26-020881.md) |
| Diluted EPS | $ per share | [(5.21)](/filings/0001558370-24-002083.md) | [(5.57)](/filings/0001558370-25-001869.md) | [(3.78)](/filings/0001104659-26-020881.md) | [(1.53)](/filings/0001104659-26-020881.md) | [(1.52)](/filings/0001104659-26-020881.md) |
| Free cash flow | $m | [(376)](/filings/0001558370-24-002083.md) | [(479)](/filings/0001558370-25-001869.md) | [(286)](/filings/0001104659-26-020881.md) | [69.2](/filings/0001104659-26-020881.md) | [109](/filings/0001104659-26-020881.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ntra/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-28 | [Brophy Michael Burkes](/insiders/1697362.md) | CHIEF FINANCIAL OFFICER, Officer | Sale (S) | 1,198 | $426.3404 | $510.8k | [Form 4](/filings/0001697362-26-000020.md) |
| 2026-10-28 | [Fesko John](/insiders/2010135.md) | PRESIDENT, CHIEF BUS. OFFICER, Officer | Sale (S) | 898 | $426.3404 | $382.9k | [Form 4](/filings/0002010135-26-000025.md) |
| 2026-10-28 | [Rabinowitz Daniel](/insiders/1857843.md) | SEC. AND CHIEF LEGAL OFFICER, Officer | Sale (S) | 968 | $426.3404 | $412.7k | [Form 4](/filings/0001857843-26-000030.md) |
| 2026-10-28 | [Chapman Steven Leonard](/insiders/1711968.md) | CEO AND PRESIDENT, Director, Officer | Sale (S) | 3,430 | $426.3404 | $1.5m | [Form 4](/filings/0001711968-26-000027.md) |
| 2026-10-28 | [Moshkevich Solomon](/insiders/2010019.md) | PRESIDENT, CLINICALDIAGNOSTICS, Officer | Sale (S) | 1,162 | $426.3404 | $495.4k | [Form 4](/filings/0002010019-26-000035.md) |
| 2026-10-27 | [Brophy Michael Burkes](/insiders/1697362.md) | CHIEF FINANCIAL OFFICER, Officer | Sale (S) | 781 | $406.00 | $317.1k | [Form 4](/filings/0001697362-26-000020.md) |
| 2026-10-27 | [Fesko John](/insiders/2010135.md) | PRESIDENT, CHIEF BUS. OFFICER, Officer | Sale (S) | 781 | $406.00 | $317.1k | [Form 4](/filings/0002010135-26-000025.md) |
| 2026-10-27 | [Rabinowitz Daniel](/insiders/1857843.md) | SEC. AND CHIEF LEGAL OFFICER, Officer | Sale (S) | 884 | $406.00 | $358.9k | [Form 4](/filings/0001857843-26-000030.md) |
| 2026-10-27 | [Chapman Steven Leonard](/insiders/1711968.md) | CEO AND PRESIDENT, Director, Officer | Sale (S) | 2,264 | $406.00 | $919.2k | [Form 4](/filings/0001711968-26-000027.md) |
| 2026-10-27 | [Rabinowitz Matthew](/insiders/1646382.md) | EXECUTIVE CHAIRMAN, Director, Officer | Sale (S) | 1,718 | $406.00 | $697.5k | [Form 4](/filings/0001646382-26-000026.md) |
| 2026-10-27 | [Moshkevich Solomon](/insiders/2010019.md) | PRESIDENT, CLINICALDIAGNOSTICS, Officer | Sale (S) | 1,010 | $406.00 | $410.1k | [Form 4](/filings/0002010019-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 165 | $416.6736 | $68.8k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 255 | $415.6659 | $106.0k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 125 | $413.0476 | $51.6k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 211 | $412.1991 | $87.0k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 605 | $411.3175 | $248.8k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 627 | $409.8932 | $257.0k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 962 | $408.2584 | $392.7k | [Form 4](/filings/0001646649-26-000035.md) |
| 2026-10-21 | [Sheena Jonathan](/insiders/1646649.md) | Director, CO-FOUNDER | Sale (S) | 200 | $406.50 | $81.3k | [Form 4](/filings/0001646649-26-000035.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $3.51bn | 12,865,346 |  | Reduced −521,321 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.96bn | 10,914,608 |  | Added +237,270 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.69bn | 6,228,216 |  | Added +219,720 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.57bn | 5,782,640 |  | Added +137,945 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.48bn | 5,451,396 |  | Added +2,897,142 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $1.10bn | 4,040,738 |  | Reduced −727,855 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $992.3m | 3,655,618 |  | Added +238,146 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $744.6m | 2,750,013 |  | Reduced −25,915 |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $739.9m | 2,725,903 |  | Added +240,578 |
| [Castle Hook Partners LP](/funds/1687241.md) | 2026-06-30 | $704.8m | 2,596,276 |  | Added +66,466 |

## Recent filings

[All 1,827 filings](/companies/ntra/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 20:00 ET | [10-Q](/filings/0001628280-26-054525.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054525 |
| 2026-08-06 | 16:05 ET | [8-K](/filings/0001604821-26-000015.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001604821-26-000015 |
| 2026-07-06 | 16:05 ET | [8-K](/filings/0001604821-26-000005.md) | 5.02 Departure or appointment of officers or directors | 0001604821-26-000005 |
| 2026-06-16 | 16:08 ET | [8-K/A](/filings/0001604821-26-000004.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001604821-26-000004 |
| 2026-06-16 | 16:06 ET | [8-K](/filings/0001604821-26-000003.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001604821-26-000003 |
| 2026-06-05 | 16:08 ET | [8-K](/filings/0001604821-26-000002.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001604821-26-000002 |
| 2026-05-08 | 19:47 ET | [10-Q](/filings/0001628280-26-032478.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032478 |
| 2026-05-07 | 16:10 ET | [8-K](/filings/0001628280-26-032101.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-032101 |
| 2026-04-23 | 16:44 ET | [DEF 14A](/filings/0001104659-26-047770.md) | Proxy statement, period 2026-06-11 | 0001104659-26-047770 |
| 2026-04-01 | 16:15 ET | [8-K](/filings/0001104659-26-038519.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-038519 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-020881.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bf2c6ba7-50e1-46d6-9e70-3d87a7eb6567)

## About the filer

- CIK: 1604821
- Tickers: NTRA
- Exchange: Nasdaq
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 21:35 ET. No prices; not investment advice.